Detailed price information for Agilent Technologies (A-N) from The Globe and Mail including charting and trades.

Emerging research in cellular reprogramming, gene editing, and regenerative medicine is driving interest in preventive longevity medicine. Some researchers argue aging may be treated as a modifiable ...

Drug delivery researchers have vastly improved the potential of genetic therapies by overcoming the challenge of consistently getting genes and gene-editing tools where they need to be within cells.

Aplantex and Investissement Québec are pleased to announce a partnership to boost the deployment of Aplantex's innovative green biotechnology. Under this partnership, Investissement Québec provides ...

People often compare the genome to a computer's program, with the cell using its genetic code to process environmental inputs and produce appropriate responses. Subscribe to our newsletter for the ...

NanoImaging Services (NIS), a leading provider of integrated gene-to-structure and cryo-electron microscopy (cryo-EM) services for structure-based drug discovery, is pleased to announce the ...

A new review outlines design principles and applications of synthetic membraneless organelles built through liquid-liquid phase separation for use in biotechnology.

Lee Knott, CEO of Advetec, explores how biotechnology is enabling operators to move beyond landfill and unlock circular value ...

The deployment of products of genetically modified organisms (GMOs) continues to raise concerns and resistance, not only in ...

The origin of many diseases begins at the cellular level and involves multiple molecular interactions. However, previous methods have struggled to accurately observe changes in individual cells.

Drug Farm today announced that the U.S. Food and Drug Administration (U.S. Food and Drug Administration, FDA) has accepted DF-003, the company's investigational therapy for ROSAH syndrome, into the ...